Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from SynAct Pharma AB ( (SE:SYNACT) ) is now available.
SynAct Pharma has appointed Ann Kristin Led as Chief Financial Officer effective 1 March 2026, strengthening its senior leadership as it advances its clinical pipeline. Led brings extensive financial and strategic experience from prior roles at MedTrace Pharma, MC2 Therapeutics, and Lundbeck, where she was instrumental in fundraising, licensing deals, and financial operations.
The leadership change comes ahead of key Phase 2b ADVANCE trial data expected at the end of the second quarter, a period the company describes as potentially transformative. SynAct expects Led’s capital markets and deal-making background to support ongoing partner discussions and execution of strategic priorities, positioning the company for growth and potential value creation for its stakeholders.
The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK22.00 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm that specializes in resolving inflammation by selectively activating the melanocortin system. Its pipeline includes a portfolio of oral and injectable melanocortin agonists designed to induce anti-inflammatory and inflammation-resolving activity, targeting patients who need to restore immune balance and control chronic inflammatory conditions.
The company focuses on translating its scientific expertise in melanocortin biology into therapies that can address unmet medical needs in inflammatory diseases. By developing both oral and injectable formats, SynAct aims to offer flexible treatment options across different care settings and indications, reinforcing its niche position in the inflammation and immunology arena.
Average Trading Volume: 139,671
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.02B
For an in-depth examination of SYNACT stock, go to TipRanks’ Overview page.